The estimated Net Worth of Yalonda Howze is at least $324 mil dollars as of 15 July 2024. Ms Howze owns over 3,347 units of Codiak BioSciences stock worth over $730 and over the last 4 years she sold CDAK stock worth over $326. In addition, she makes $322,884 as Exec. VP, Chief Legal Officer y Chief Compliance Officer & Corp. Sec. at Codiak BioSciences.
Ms has made over 5 trades of the Codiak BioSciences stock since 2022, according to the Form 4 filled with the SEC. Most recently she exercised 3,347 units of CDAK stock worth $191 on 15 July 2024.
The largest trade she's ever made was exercising 13,388 units of Codiak BioSciences stock on 15 April 2024 worth over $763. On average, Ms trades about 2,291 units every 50 days since 2020. As of 15 July 2024 she still owns at least 12,805 units of Codiak BioSciences stock.
You can see the complete history of Ms Howze stock trades at the bottom of the page.
Yalonda Howze is the Exec. VP, Chief Legal Officer, Chief Compliance Officer & Corp. Sec. at Codiak BioSciences.
As the Exec. VP, Chief Legal Officer y Chief Compliance Officer & Corp. Sec. of Codiak BioSciences, the total compensation of Ms Howze at Codiak BioSciences is $322,884. There are 2 executives at Codiak BioSciences getting paid more, with Dr. Douglas Edward Williams Ph.D. having the highest compensation of $863,681.
Ms Howze is 49, she's been the Exec. VP, Chief Legal Officer y Chief Compliance Officer & Corp. Sec. of Codiak BioSciences since . There are 5 older and 3 younger executives at Codiak BioSciences. The oldest executive at Codiak BioSciences, Inc. is Richard Brudnick, 64, who is the Chief Bus. Officer & Head of Corp. Strategy.
Yalonda's mailing address filed with the SEC is C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE, MA, 02142.
Over the last 4 years, insiders at Codiak BioSciences have traded over $15,220 worth of Codiak BioSciences stock and bought 11,821,475 units worth $20,798,957 . The most active insiders traders include Steven Gillis, Venture Fund Viii, L.P.Arch... y Permanent Fund Corp Alaska. On average, Codiak BioSciences executives and independent directors trade stock every 25 days with the average trade being worth of $19,158. The most recent stock trade was executed by Yalonda Howze on 30 March 2023, trading 1,628 units of CDAK stock currently worth $326.
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Codiak BioSciences executives and other stock owners filed with the SEC include: